Dr. STEPHEN SALLOWAY, director of Butler Hospital’s Memory and Aging Program for the past 25 years, will step down and hand over the reins to the program’s associate director, Dr. Meghan Riddle. / COURTESY BUTLER HOSPITAL
PROVIDENCE – Dr. Butler Hospital’s Stephen Salloway, a neurologist who has received international recognition for his research into treatments for Alzheimer’s disease, will resign from his position as director of the hospital’s Memory and Aging Program.
Salloway will hand over the leadership of the program, which he has held for 25 years, to associate director, Dr. Meghan Riddle. She will act as interim director until a new director is appointed.
The hospital has launched a nationwide search for Salloway’s successor.
Salloway received national attention for his research into the development of Aduhelm, a drug developed by Biogen Inc. was created to slow the progression of Alzheimer’s disease in patients with mild to moderate cases of the disease.
Under Salloway’s leadership, Butler has conducted more than 100 clinical trials for treatments for Alzheimer’s disease and related dementias.
Salloway will continue to work on research studies in the Memory and Aging Program and serve as an advisor to Riddle. He will also continue as a professor of psychiatry and neurology at Brown University’s Warren Alpert Medical School, and as an associate director of the Brown University Center for Alzheimer’s Disease Research.
“Thanks to the dedication of our staff and the contribution of thousands of study volunteers, the Memory and Aging Program has become a leading international center for Alzheimer’s research,” Salloway said. “Working together, we have opened the modern era of Alzheimer’s disease treatment and I look forward to continuing to work with the Butler Memory and Aging Program and the Brown Center for Alzheimer’s Disease Research to make exciting new advances in the fight against Alzheimer’s disease. disease.”
Salloway’s extensive research includes work on a trial that showed that the diagnosis and treatment of mild dementia can be improved by using a scan to detect plaque buildup in the brain. He also co-authored a study showing that brain damage leading to Alzheimer’s can be detected by a blood test up to 16 years before symptoms appear.
“As director of neurology and the memory and aging program at Butler Hospital, Dr. Salloway has been a tremendous asset to Butler Hospital and to individuals suffering from Alzheimer’s disease,” said Butler CEO and President Mary Marran. “Dr. Salloway is internationally known for his work advancing the diagnosis and treatment of this terrible disease, and we will remain eternally grateful that he has dedicated his career to this effort.”
Elizabeth Graham is a contributing writer to PBN.
Do you want to share this story? Click here to buy a link that will allow anyone to read it on any device, whether they are a subscriber or not.
This post Salloway steps down as director of Butler’s Memory and Aging Program
was original published at “https://pbn.com/salloway-to-step-down-as-butlers-memory-and-aging-program-director/”